Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

Phase 3

Conditions: Major Depressive Disorder

First Posted Date: 2005-10-17

Last Posted Date: 2012-05-09

Lead Sponsor: Pharmacology Research Institute

Registration Number: NCT00239954

Locations: 🇺🇸
Pharmacology Research Institute, Riverside, California, United States

Investigation of a Combination Treatment of Escitalopram and rTMS

Not Applicable

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2005-10-05

Last Posted Date: 2011-06-23

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 42

Registration Number: NCT00232700

Locations: 🇩🇪
Department of Psychiatry, Charité - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

First Posted Date: 2005-10-04

Last Posted Date: 2010-12-07

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT00231335

Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia

Phase 4

Conditions: Depressive Syndrome

First Posted Date: 2005-09-29

Last Posted Date: 2006-08-29

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 40

Registration Number: NCT00229333

Locations: 🇮🇱
Sheba Medical Center, Ramat Gan, Israel

Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain

Phase 4

Withdrawn

Conditions: Low Back Pain
Depression

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2005-09-28

Last Posted Date: 2014-06-17

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Registration Number: NCT00227292

Locations: 🇩🇪
Martin-Luther-University Halle, Halle, Sachsen-Anhalt, Germany

Impact of Caregiver Depression on Asthma in the Child

Completed

Conditions: Asthma
Depressive Disorder, Major

First Posted Date: 2005-09-22

Last Posted Date: 2011-08-03

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 175

Registration Number: NCT00223288

Locations: 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study

Phase 4

Completed

Conditions: Major Depression

First Posted Date: 2005-09-22

Last Posted Date: 2005-09-22

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 35

Registration Number: NCT00222820

Locations: 🇺🇸
Western Psychaitric Institute and Clinic, Pittsburgh, Pennsylvania, United States

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Phase 2

Completed

Conditions: OCD

Interventions: Drug: Placebo ( sugar pill)
Drug: escitalopram

First Posted Date: 2005-09-22

Last Posted Date: 2014-07-23

Lead Sponsor: Duke University

Target Recruit Count: 14

Registration Number: NCT00215137

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

Phase 4

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Behavioral: Cognitive Behavioral Therapy
Drug: escitalopram

First Posted Date: 2005-09-22

Last Posted Date: 2017-12-19

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 25

Registration Number: NCT00219349

Locations: 🇺🇸
Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States

A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression

Not Applicable

Conditions: Depressive Disorder, Major

First Posted Date: 2005-09-22

Last Posted Date: 2010-02-09

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 60

Registration Number: NCT00220480

Locations: 🇮🇱
Ness Ziona Mental Health Center, Ness Ziona, Israel
🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱
Chaim Sheba Medical Center, Ramat-Gan, Israel

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy